FR3110393B1 - Compose et composition pour induire une neuroprotection - Google Patents
Compose et composition pour induire une neuroprotection Download PDFInfo
- Publication number
- FR3110393B1 FR3110393B1 FR2005138A FR2005138A FR3110393B1 FR 3110393 B1 FR3110393 B1 FR 3110393B1 FR 2005138 A FR2005138 A FR 2005138A FR 2005138 A FR2005138 A FR 2005138A FR 3110393 B1 FR3110393 B1 FR 3110393B1
- Authority
- FR
- France
- Prior art keywords
- compound
- composition
- inducing neuroprotection
- neuroprotection
- inducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2005138A FR3110393B1 (fr) | 2020-05-20 | 2020-05-20 | Compose et composition pour induire une neuroprotection |
| PCT/FR2021/050929 WO2021234324A1 (fr) | 2020-05-20 | 2021-05-20 | Compose et composition pour induire une neuroprotection |
| CN202180060125.1A CN116981449A (zh) | 2020-05-20 | 2021-05-20 | 用于引起神经保护的化合物和组合物 |
| CA3178633A CA3178633A1 (fr) | 2020-05-20 | 2021-05-20 | Compose et composition pour induire une neuroprotection |
| EP21734182.5A EP4142703B8 (fr) | 2020-05-20 | 2021-05-20 | Composé et composition pour induire une neuroprotection |
| JP2022571216A JP2023531869A (ja) | 2020-05-20 | 2021-05-20 | 神経保護を誘導するための化合物及び組成物 |
| KR1020227044712A KR20230013116A (ko) | 2020-05-20 | 2021-05-20 | 신경보호 유도용 화합물 및 조성물 |
| US17/924,420 US12611387B2 (en) | 2020-05-20 | 2021-05-20 | Compound and composition for inducing neuroprotection |
| ES21734182T ES2970378T3 (es) | 2020-05-20 | 2021-05-20 | Compuesto y composición para inducir la neuroprotección |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2005138A FR3110393B1 (fr) | 2020-05-20 | 2020-05-20 | Compose et composition pour induire une neuroprotection |
| FR2005138 | 2020-05-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3110393A1 FR3110393A1 (fr) | 2021-11-26 |
| FR3110393B1 true FR3110393B1 (fr) | 2022-05-06 |
Family
ID=73013493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2005138A Active FR3110393B1 (fr) | 2020-05-20 | 2020-05-20 | Compose et composition pour induire une neuroprotection |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12611387B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4142703B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023531869A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230013116A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116981449A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178633A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2970378T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR3110393B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021234324A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3149773B1 (fr) | 2023-06-19 | 2026-04-17 | Rest Therapeutics | Nouvelles combinaisons synergiques a base de fenm |
| FR3163834A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine |
| WO2026003229A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament |
| FR3163835B1 (fr) | 2024-06-26 | 2026-06-26 | Rest Therapeutics | Derives de fluoroethylnormemantine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100339070C (zh) * | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| BRPI0516112A (pt) * | 2004-10-15 | 2008-08-26 | Janssen Pharmaceutica Nv | métodos para neuroproteção |
| US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
| FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| US20120115943A1 (en) * | 2008-10-01 | 2012-05-10 | National Taiwan University | Composition and method for neuroprotection against excitotoxic injury |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| FR3006193B1 (fr) * | 2013-05-29 | 2015-06-19 | Holis Technologies | Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda) |
| FR3050732B1 (fr) | 2016-05-02 | 2019-06-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques |
| FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
| WO2020232246A1 (en) * | 2019-05-15 | 2020-11-19 | The Trustees Of Columbia University In The City Of New York | Compositions and methods against stress-induced affective disorders and their associated symptoms |
-
2020
- 2020-05-20 FR FR2005138A patent/FR3110393B1/fr active Active
-
2021
- 2021-05-20 ES ES21734182T patent/ES2970378T3/es active Active
- 2021-05-20 US US17/924,420 patent/US12611387B2/en active Active
- 2021-05-20 CN CN202180060125.1A patent/CN116981449A/zh active Pending
- 2021-05-20 KR KR1020227044712A patent/KR20230013116A/ko active Pending
- 2021-05-20 EP EP21734182.5A patent/EP4142703B8/fr active Active
- 2021-05-20 CA CA3178633A patent/CA3178633A1/fr active Pending
- 2021-05-20 WO PCT/FR2021/050929 patent/WO2021234324A1/fr not_active Ceased
- 2021-05-20 JP JP2022571216A patent/JP2023531869A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR3110393A1 (fr) | 2021-11-26 |
| EP4142703B8 (fr) | 2023-11-22 |
| EP4142703A1 (fr) | 2023-03-08 |
| CA3178633A1 (fr) | 2021-11-25 |
| CN116981449A (zh) | 2023-10-31 |
| EP4142703C0 (fr) | 2023-10-18 |
| WO2021234324A1 (fr) | 2021-11-25 |
| US12611387B2 (en) | 2026-04-28 |
| ES2970378T3 (es) | 2024-05-28 |
| EP4142703B1 (fr) | 2023-10-18 |
| KR20230013116A (ko) | 2023-01-26 |
| JP2023531869A (ja) | 2023-07-26 |
| US20230270695A1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54229B1 (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA31504B1 (fr) | Acides benzoylamino-indan-2-carboxyliques substitues et composes apparentes | |
| CR20200376A (es) | Inhibidores de cd73 | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| MA58170B1 (fr) | Dérivés carboxy avec des proprietes anti-inflammatoires | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| JOP20200194A1 (ar) | صور بلورية جديدة | |
| MX2020009956A (es) | Compuestos para el tratamiento de enfermedad de hungtinton. | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA58993A1 (fr) | Antagoniste du récepteur crf1 pour le traitement de l'hyperplasie surrénale congénitale | |
| DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| EP3569601A3 (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| MX2021006265A (es) | Derivados de panteteina y usos de los mismos. | |
| PH12020551580A1 (en) | Piperidine compounds as covalent menin inhibitor-0s | |
| EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA33767B1 (fr) | Nouvelle utilisation anticancéreuse du cabazitaxel | |
| MA33840B1 (fr) | Nouveau composé de spiropipéridine | |
| MA38826B1 (fr) | Nouveaux dérivés de triazolo[4,5-d]pyrimidine | |
| JOP20210039B1 (ar) | مركبات بيريدين 6،2 - ديامينو | |
| MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| BR112017016428A2 (pt) | ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório? | |
| MA30704B1 (fr) | Compositions therapeutiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20211126 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| TQ | Partial transmission of property |
Owner name: ECOLE PRATIQUE DES HAUTES ETUDES, FR Effective date: 20220531 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR Effective date: 20220531 Owner name: UNIVERSITE DE MONTPELLIER, FR Effective date: 20220531 Owner name: REST THERAPEUTICS, FR Effective date: 20220531 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |
|
| CA | Change of address |
Effective date: 20231214 |
|
| PLFP | Fee payment |
Year of fee payment: 5 |
|
| CL | Concession to grant licences |
Name of requester: AXLR, SATT OCCITANIE MEDITERRANEE, FR Effective date: 20240530 |
|
| PLFP | Fee payment |
Year of fee payment: 6 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |